Insider Selling: Pulmonx (NASDAQ:LUNG) Insider Sells $17,806.54 in Stock

Pulmonx Corporation (NASDAQ:LUNG) insider Geoffrey Rose sold 7,879 shares of the stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $2.26, for a total transaction of $17,806.54. Following the sale, the insider directly owned 449,832 shares of the company’s stock, valued at $1,016,620.32. This represents a 1.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Pulmonx Stock Down 2.2%

Shares of NASDAQ LUNG opened at $2.21 on Friday. Pulmonx Corporation has a 52-week low of $1.13 and a 52-week high of $2.89. The company has a debt-to-equity ratio of 0.95, a quick ratio of 3.52 and a current ratio of 4.32. The company’s 50 day moving average price is $1.82 and its 200-day moving average price is $1.57. The company has a market capitalization of $94.92 million, a P/E ratio of -1.91 and a beta of 0.34.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, July 29th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. The business had revenue of $22.76 million during the quarter, compared to the consensus estimate of $22.39 million. Pulmonx had a negative net margin of 55.03% and a negative return on equity of 96.66%. Equities analysts forecast that Pulmonx Corporation will post -1.05 earnings per share for the current year.

Institutional Trading of Pulmonx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LUNG. Hsbc Holdings PLC grew its holdings in Pulmonx by 1,275.8% during the second quarter. Hsbc Holdings PLC now owns 193,846 shares of the company’s stock worth $249,000 after buying an additional 179,756 shares in the last quarter. Stonepine Capital Management LLC bought a new stake in Pulmonx in the 2nd quarter worth about $1,060,067. Jefferies Financial Group Inc. bought a new stake in Pulmonx in the 2nd quarter worth about $371,000. Almitas Capital LLC purchased a new stake in Pulmonx in the 2nd quarter valued at about $1,383,000. Finally, ADAR1 Capital Management LLC purchased a new stake in Pulmonx in the 2nd quarter valued at about $526,000. 91.04% of the stock is owned by institutional investors.

More Pulmonx News

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Analyst sentiment remains broadly favorable, with three Buy ratings and one Sell rating producing a “Moderate Buy” consensus. The average price target of $7.67 is substantially above recent trading levels, suggesting significant potential upside if Pulmonx delivers on its growth plans. Pulmonx analyst and earnings information
• Positive Sentiment: Pulmonx’s latest quarterly results exceeded expectations: revenue was $22.76 million versus the $22.39 million consensus estimate, while its loss of $0.24 per share was narrower than the expected $0.28 loss. Pulmonx quarterly results
• Neutral Sentiment: CEO Glendon French III, General Counsel David Lehman, Geoffrey Rose and Srikanth Radhakrishnan sold a combined 78,340 shares at approximately $2.26 per share. The filings say the transactions covered tax-withholding obligations related to vested equity awards, reducing their significance as a signal of declining confidence; however, the sales may add modest short-term supply. Pulmonx insider sales report
• Negative Sentiment: Recent gains have triggered profit-taking, contributing to the stock’s retreat and weakening short-term trading sentiment. Pulmonx shares fall following recent gains
• Negative Sentiment: Pulmonx remains unprofitable, and analysts expect a full-year loss of roughly $1.05 per share. The company’s negative margins and uncertain path to sustained profitability are keeping investors cautious despite the earnings beat. Pulmonx profit-taking and earnings outlook

Analyst Upgrades and Downgrades

LUNG has been the topic of several research analyst reports. Weiss Ratings upgraded Pulmonx from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 25th. Wall Street Zen raised shares of Pulmonx from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Pulmonx presently has a consensus rating of “Moderate Buy” and an average price target of $7.67.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.